Buscar en
Acta Otorrinolaringológica Española
Toda la web
Inicio Acta Otorrinolaringológica Española Expression of E-cadherin and β-catenin in Laryngeal and Hypopharyngeal Squamous...
Journal Information
Vol. 71. Issue 6.
Pages 358-366 (November - December 2020)
Share
Share
Download PDF
More article options
ePub
Visits
3
Vol. 71. Issue 6.
Pages 358-366 (November - December 2020)
Original article
DOI: 10.1016/j.otoeng.2019.12.003
Expression of E-cadherin and β-catenin in Laryngeal and Hypopharyngeal Squamous Cell Carcinomas
Expresión de E-cadherina y β-catenina en carcinomas de células escamosas de laringe e hipofaringe
Visits
...
Patricia García-Caboa,b,
Corresponding author
patriciagcabo@gmail.com

Corresponding author.
, Juana María García-Pedrerob, M. Ángeles Villarongab, Francisco Hermida-Pradob, Rocío Granda-Díazb, Eva Alloncab, Fernando Lópeza,b, Juan Pablo Rodrigoa,b
a Servicio de Otorrinolaringología, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain
b Instituto Universitario de Oncología de Principado de Asturias, Universidad de Oviedo, Oviedo, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (4)
Table 1. Expression of E-cadherin and β-catenin in Relation to the Clinical and Pathological Characteristics in Patients With SCC of the Larynx
Table 2. Expression of E-cadherin and β-catenin in Relation to the Clinical and Pathological Characteristics in Patients With Hypopharyngeal SCC
Table 3. Multivariate Analysis of Risk Factors for Specific Survival and Disease-specific Survival in Patients With SCC of the Larynx
Table 4. Multivariate Analysis of Risk Factors for Specific Survival and Disease-specific Survival in Patients With SCC of the Hypo Pharynx
Show moreShow less
Abstract
Introduction and objectives

dysfunction of the E-cadherin/catenin complex is directly related to carcinogenesis and metastases development.

The aim of this paper is to investigate the prognostic significance of E-cadherin and β-catenin expression in surgically treated laryngeal and hypopharyngeal squamous cell carcinomas.

Material and methods

Tumour tissue samples were obtained from 133 consecutive patients with squamous cell carcinomas of the head and neck: 68 of the larynx and 65 hypopharyngeal carcinomas, who underwent surgical treatment in our hospital between 2000 and 2005.

E-cadherin and β-catenin expression was analysed by immunohistochemistry, quantifying the percentage of stained cells and the intensity of staining.

Results

E-cadherin and β-catenin expression was evaluable in 59 laryngeal carcinomas and in 58 cases of hypopharyngeal carcinomas.

In the laryngeal tumours, a significant association was found between the low expression of membrane β-catenin with T4 tumours and tumour recurrence. In the hypopharynx there was a significant association between positive expression of nuclear β-catenin and poor histological differentiation (P = .02). In the multivariate analysis, only the presence of lymph node metastases was an independent predictive factor of decreased disease-specific survival in laryngeal squamous cell carcinomas.

Conclusions

The expression of E-cadherin and β-catenin does not show prognostic significance in laryngeal and hypopharyngeal squamous cell carcinomas over the TNM classification.

Keywords:
E-cadherin
β-catenin
Squamous cell carcinoma
Larynx
Hypopharynx
Resumen
Introducción y objetivos

La disfunción del complejo E-cadherina/catenina está relacionada directamente con la carcinogénesis y el desarrollo de metástasis.

El objetivo de este trabajo es investigar el significado pronóstico de la expresión de E-cadherina y β-catenina en carcinomas de células escamosas de laringe e hipofaringe tratados quirúrgicamente.

Material y métodos

Se obtuvieron muestras de tejido tumoral de 133 pacientes consecutivos con carcinomas escamosos de cabeza y cuello: 68 de laringe y 65 carcinomas de hipofaringe, que fueron sometidos a tratamiento quirúrgico en nuestro hospital entre 2000 y 2005.

La expresión de E-cadherina y β-catenina se analizó mediante inmunohistoquímica, cuantificando el porcentaje de células teñidas y la intensidad de la tinción.

Resultados

La expresión de E-cadherina y β-catenina fue evaluable en 59 muestras de carcinomas de laringe y en 58 de hipofaringe.

En tumores de laringe se observó una asociación significativa entre la baja expresión de β-catenina de membrana y tumores avanzados T4 y la recidiva tumoral. A nivel de hipofaringe se encontró una asociación significativa de la expresión positiva de β-catenina nuclear con pobre diferenciación histológica (P = 0,02). En el análisis multivariante sólo la presencia de metástasis ganglionares era factor predictor independiente de disminución de la supervivencia específica para enfermedad en carcinoma de células escamosas de laringe.

Conclusiones

La expresión de E-cadherina y β-catenina no parece tener utilidad pronóstica superior al TNM en los carcinomas epidermoides de laringe e hipofaringe.

Palabras clave:
E-cadherina
β-catenina
Carcinoma células escamosas
Laringe
Hipofaringe

Article

These are the options to access the full texts of the publication Acta Otorrinolaringológica Española
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Acta Otorrinolaringológica Española

Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 19,34 €

Comprar ahora
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.